
This meta-analysis of 18 randomized clinical trials involving 3820 patients evaluated the efficacy of drug-coated balloons (DCBs), drug-eluting stents (DES), and plain old balloon angioplasty (POBA) for treating coronary in-stent restenosis. Both DCB and DES significantly reduced major adverse cardiovascular events and target lesion revascularization compared with POBA. While DCBs had a lower postprocedural minimum lumen diameter, they showed less late lumen loss compared with DES. Overall, no significant difference in clinical outcomes was observed between DCB and DES, highlighting DCBs as an effective alternative for ISR management.
Like
Save
Share